Hospital) from the Medical Research Council (Grant No. 973/787/K).

References and Notes

(1) S. K. Carter and M. A. Friedman, *Eur. J. Cancer*, 8, 85 (1972).
(2) D. A. Clarke, R. K. Barclay, C. C. Stock, and C. S. Rondestvet, Jr., *Proc. Soc. Exp. Biol. Med.*, **90**, 484 (1955).
(3) J. H. Burchenal, M. K. Dagg, M. Beyer, and C. C. Stock, *Proc. Soc. Exp. Biol. Med.*, 91, 398 (1956).
(4) R. C. S. Audette, T. A. Connors, H. G. Mandel, K. Merai, and W. C. J. Ross, *Biochem. Pharmacol.*, **22**, 1855 (1973).
(5) T. A. Connors, P. M. Goddard, K. Merai, W. C. J. Ross, and D. E. V. Wilman, *Biochem. Pharmacol.*, **25**, 241 (1976).
(6) Y. T. Lin, T. L. Loo, S. Vadlamudi, and A. Goldin, *J. Med. Chem.*, **15**, 201 (1972).
(7) Y. F. Shealy, C. A. O'Dell, J. D. Clayton, and C. A. Krauth, *J. Pharm. Sci.*, **60**, 1426 (1971).
(8) R. L. Hinman and M. C. Flores, *J. Org. Chem.*, **24**, 660 (1959).
(9) P. A. S. Smith, "Open Chain Nitrogen Compounds", Vol. II, W. A. Benjamin, New York, N.Y., 1966, p 255.
(10) G. W. Anderson, H. E. Faith, H. W. Marson, P. S. Winnek, and R. O. Roblin, Jr., *J. Am. Chem. Soc.*, **64**, 2902 (1942).
(11) I. Lalezari and F. Afghahi, *J. Pharm. Sci.*, **64**, 698 (1975).
(12) G. W. Snedecor and W. G. Cochran, "Statistical Methods", 6th ed, Iowa State University Press, Ames, Iowa, 1967, pp 258–298.

Antiinflammatory Activity of 17-Esters of 6α,9α-Difluoro-21-deoxyprednisolone

Romano Vitali, Serafino Gladiali,[1a] Giovanni Falconi,[1b] Giuseppe Celasco, and Rinaldo Gardi*

Vister Research Laboratories, Casatenovo (Como), Italy. *Received November 30, 1976*

Several 17-monoesters of 6α,9α-difluoro-21-deoxyprednisolone were prepared and tested for their antiinflammatory activity. Propionate **11** and butyrate **12** displayed a high topical activity.

The availability of corticosteroid 17-monoesters, via 17,21-orthoesters,[2] allowed us to develop a general route to their 21-deoxy analogues by reductive elimination of the 21-hydroxyl group.[3] In spite of the lack of a function considered essential for the corticoid activity, some 21-deoxycorticosteroids have been reported to display topical antiinflammatory activity,[4] which is markedly increased by the presence of protective groups at C-16 and C-17 like acetonides[5] and esters at C-17.[6]

In a previous paper we described the high antiinflammatory activity of 17,21-alkyl orthoesters, 17-monoesters, and 17,21-diesters of 6α,9α-difluoroprednisolone.[7] Here we wish to report the synthesis and some biological properties of 17-esters of 6α,9α-difluoro-21-deoxyprednisolone.

The compounds were obtained from 6α,9α-difluoroprednisolone 17-monoesters according to the already published procedure[3] involving the preparation of the 21-tosylates and the subsequent reduction in situ through the corresponding 21-iodo derivatives.

Yields, melting points, specific optical rotations, and analytical data of the compounds are given in Table I.

Biology and Evaluation. The 17-esters of 6α,9α-difluoro-21-deoxyprednisolone **10–13** have been assayed for their antiexudative activity by the granuloma pouch test according to Selye.[8] The compound was injected into the pouch of rats on day 5 or injected subcutaneously daily from day 2 to day 10. Autopsy was performed on day 11.

The compounds have been assayed also in the vasoconstriction test on volunteers according to the modification described by Falconi and Rossi.[9] In all cases reference compounds have also been tested. The results are shown in Tables II and III.

With the exception of acetate **10**, the 21-deoxy-17-esters displayed a high local antiexudative activity, greater than that of free deoxydifluoroprednisolone **14**[10] and of the corresponding 21-hydroxy esters investigated, propionate **2** and benzoate **4**. Evaluation of **13** vs. **4** in the same test after daily subcutaneous treatment revealed that the 21-deoxy derivative displayed a lower systemic antiexudative activity.

In the vasoconstriction test, compounds **10–12** proved

Table I



No.	R	X	Yield,[a] %	Mp, °C	$[\alpha]_D$, deg	Formula	Analyses
4	C_6H_5	OH	70	228–231	+14.2	$C_{28}H_{30}F_2O_6$	C, H
7	C_2H_5	OTs	89	205–207	+14	$C_{31}H_{36}F_2O_8S$	C, H, S
8	C_3H_7	OTs	98	125[b]	−12.2	$C_{32}H_{38}F_2O_8S$	C, H, S
9	C_6H_5	OTs	85	204–206	−21	$C_{35}H_{36}F_2O_8S$	C, H, S
10	CH_3	H	45[c]	258–260	+24	$C_{23}H_{28}F_2O_5$	C, H
11	C_2H_5	H	72	235–237	+20.5	$C_{24}H_{30}F_2O_5$	C, H
12	C_3H_7	H	68	219–221	−19.7	$C_{25}H_{32}F_2O_5$	H[d]
13	C_6H_5	H	54	282–284	−6.6	$C_{28}H_{30}F_2O_5$	C, H

[a] Yield is of analytically pure material. [b] With decomposition. [c] Overall yield. Intermediate 21-tosylate **6** was not isolated. [d] C: calcd, 66.65; found, 66.20.

Table II. Antiexudative Activity[a]

Compd	% inhibn of exudate formation	
	0.002 μmol	0.02 μmol
10[b]	18	13
11[b]	47	67
12[b]	60	81
13[b]	71	90
14[b]	<5	35
2[b]	<5	41
4[b]	46	70
13[c]	<5	35
4[c]	20	62

[a] Data obtained from three different assays, each dose group including ten rats. All compounds dissolved in sesame oil. [b] Single treatment into pouch with the doses indicated. [c] Subcutaneous treatment for 9 days with the daily doses indicated.

to be markedly more active than betamethasone 17-valerate. On the basis of already published data, they are more active than the corresponding 21-hydroxy derivatives but less active than many 6,9-difluoroprednisolone 17,21-diesters.[7]

Our results confirm that the 21-hydroxy group is not essential for the antiinflammatory activity, if substituents are present which are able to increase the energy of binding with the receptors and/or the metabolic stability. In particular, compounds **11** and **12** displayed a topical antiinflammatory activity comparable with that of the most active known compounds.

Experimental Section

Melting points were taken in a capillary apparatus and are uncorrected. Optical rotations were determined in dioxane at 24 °C ($c \sim 1$). UV were determined in 95% EtOH and IR in Nujol mull. Absorption bands of these spectra were as expected. TLC were done using 250-μ thin layers (Fluorosil G) and 8:2 C_6H_6–Me_2CO. All analytical samples appeared as single spots on TLC. Where analyses are indicated only by symbols of the elements, analytical results obtained for these elements were within ±0.4% of the theoretical values.

6α,9α-Difluoroprednisolone 17-Monoesters (1–4). Acetate **1**, propionate **2**, and butyrate **3** were known from the previous work of Gardi et al.[7] The benzoate **4** was prepared by a modified procedure[11] utilizing 6α,9α-difluoroprednisolone 17,21-methyl orthobenzoate (**5**) as starting material: mp 204–206 °C; [α] +57°. Anal. ($C_{29}H_{32}F_2O_6$) C, H.

21-Tosylates (6–9). To a solution, cooled at 0 °C, of the proper 17-monoester (10 g) in 1:1 Py–CH_2Cl_2 (100 mL), TsCl (15 g) dissolved in 1:1 Py–CH_2Cl_2 (100 mL) was added. After keeping overnight at 0–5 °C, the mixture was poured into ice–water. Products were isolated as usual and recrystallized from CH_2Cl_2–Et_2O. Acetate **6**, which failed to crystallize, was not fully isolated and characterized.

21-Deoxy-17-esters (10–13). To a solution of the proper 21-tosylate (5 g) in Me_2CO (500 mL), NaI (25 g) was added. The reaction mixture was refluxed for 50 h, then treated with AcOH (30 mL), and further refluxed for 1 h. After addition of a 10% aqueous solution of $NaHSO_3$ (250 mL) and concentration under reduced pressure, the product was recovered by filtration and crystallized from Me_2CO–Et_2O.

Table III. Vasoconstrictive Activity in Man[a]

Compd	Rel potency
Betamethasone 17-valerate	1
10	1.5
11	2.5-3
12	2.5-3
13	≤1

[a] Each compound was tested on 24 subjects at three dose levels (0.02, 0.06, and 0.18 μg).

Acknowledgment. The authors are indebted to Dr. C. Pedrali for the spectral determinations.

References and Notes

(1) (a) Istituto di Chimica Organica, Università di Sassari, Italy. (b) Farmitalia, Farmacologia Sperimentale, Nerviano (Milano), Italy.
(2) R. Gardi, R. Vitali, and A. Ercoli, *Tetrahedron Lett.*, 448 (1961); R. Gardi, R. Vitali, and A. Ercoli, *Gazz. Chim. Ital.*, **93**, 431 (1962).
(3) R. Vitali, R. Gardi, and A. Ercoli, *Gazz. Chim. Ital.*, **96**, 1115 (1966).
(4) C. A. Schlagel, *J. Pharm. Sci.*, **54**, 335 (1965).
(5) R. Deghenghi, M. Boulerice, J. G. Rochefort, S. H. Sehgal, and D. J. Marshall, *J. Med. Chem.*, **9**, 513 (1966).
(6) M. J. Busse, P. Hunt, K. A. Lees, P. N. D. Maggs, and T. G. McCorthy, *Br. J. Dermatol.*, **81** (Suppl. 4), 103 (1969).
(7) R. Gardi, R. Vitali, G. Falconi, and A. Ercoli, *J. Med. Chem.*, **15**, 556 (1972).
(8) H. Selye, *Proc. Soc. Exp. Biol. Med.*, **82**, 328 (1953).
(9) G. Falconi and G. Rossi, *Arch. Dermatol.*, **105**, 856 (1972).
(10) J. A. Hogg, G. B. Spero, J. L. Thompson, B. J. Magerlein, A. P. Schneider, D. H. Peterson, O. K. Sebek, H. C. Murray, J. C. Babcock, R. L. Pederson, and J. A. Campbell, *Chem. Ind. (London)*, 1002 (1958).
(11) A. Ercoli, G. Falconi, R. Gardi, and R. Vitali, *J. Med. Chem.*, **15**, 783 (1972).